Small Caps to Watch: Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) Up 14.12%, North American Palladium Ltd (USA) (NYSEMKT:PAL) Up 14.29%
Northern, WI 05/20/2013 (GDPInsider) – Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) opened today’s trading at 3.85, having closed previously at 3.40. The strong start on open has since been bettered and ROSG is up 13.24%. The stock is trading on volume of 235.58K and has a range of 3.70 and 3.98. At present market valuation, ROSG is up 25.24% on its 52-week low of 3.09 but down 83.48% on its 52-week high of 23.43.
ROSG develops and commercializes diagnostic tests based on discovered group of genes known as microRNAs and the company launched its 5th product in July 2011 called miRview lung. Since then the company has been conducting tests on several products and recently announced an credentialing agreement with Prime Health Services, Inc, a managed care company. The deal will see Prime Health including ROSG’s miRview mets2 in the company’s portfolio of products and services.
EPS for ROSG is expected to increase by 68.18% and analysts have set a target price of 10.00 for the stock. ROSG is currently down 0.40% on its SMA50 but up 15.11% on its SMA20. The technical chart shows a very flat valuation for much of May but recent trading has shown a slight uptick.
Is ROSG a solid investment at these levels? Get exclusive data and trends here.
North American Palladium Ltd (USA) (NYSEMKT:PAL) started the day’s trading at 1.07, a clear 0.02 above its previous close of 1.05. The stock is up 14.29% on strong trading volume of 2.715 million shares. The day’s range is 1.07 and 1.23 and at current valuation PAL is down 52.59% on its 52-high low of 2.47. The stock is however, climbing north on its lowest support levels and is up 21.98% on its 52-week low of 0.96.
PAL is a leading precious metals producer that has been operating its flagship Lac des Iles mine (LDI) located in Ontario, Canada. The company also operates the Vezza gold mine located in the Abitibi region of Quebec.
PAL expects EPS next year to rise 122.20% and analysts have set a target price of 1.67 for the stock. The stock has a RSI of 45.15, indicating that at current valuation, PAL is neither oversold nor overbought. There are 178.37 million shares outstanding and insider own 11.88% of the shares being traded in PAL. Institutions own 24.58% and their share of the transactions is down 1.48%.
Should Investors Trade PAL Now? Get exclusive insights and updates here.
WallStreetAnalyzed.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetAnalyzed.com website, for complete risks and disclosures.